Cell targeting and immunostimulatory properties of a novel Fcγ-receptor-independent agonistic anti-CD40 antibody in rhesus macaques
暂无分享,去创建一个
A. Cagigi | F. Nimmerjahn | K. Loré | M. Buggert | S. Ols | U. Pessara | J. F. Højen | F. Hellgren | K. Lenart | R. Cerveira | Xianglei Yan | Stephan Fischer | Kewei Ye | Daniel Parera | Sebastian Ols | Fredrika Hellgren
[1] I. Amit,et al. Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting , 2022, Nature Cancer.
[2] R. Brink,et al. The unique biology of germinal center B cells. , 2021, Immunity.
[3] M. Cragg,et al. TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity , 2021, Communications biology.
[4] Yun-jung Kim,et al. Preclinical immunogenicity testing using anti-drug antibody analysis of GX-G3, Fc-fused recombinant human granulocyte colony-stimulating factor, in rat and monkey models , 2021, Scientific Reports.
[5] Q. Cheng,et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer , 2021, Journal of experimental & clinical cancer research : CR.
[6] Christopher R. Cabanski,et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. , 2021, The Lancet. Oncology.
[7] J. Ravetch,et al. The role of IgG Fc receptors in antibody-dependent enhancement , 2020, Nature Reviews Immunology.
[8] R. Wyatt,et al. Route of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity. , 2020, Cell reports.
[9] R. Vonderheide. CD40 Agonist Antibodies in Cancer Immunotherapy. , 2020, Annual review of medicine.
[10] K. Foulds,et al. Monocytes Acquire the Ability to Prime Tissue-Resident T Cells via IL-10-Mediated TGF-β Release , 2019, Cell reports.
[11] P. Kubes,et al. The Neutrophil's Role During Health and Disease. , 2019, Physiological reviews.
[12] R. Desrosiers,et al. Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.
[13] James M. Boyer,et al. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy , 2018, Cancer Immunology, Immunotherapy.
[14] J. Ravetch,et al. Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity , 2018, Proceedings of the National Academy of Sciences of the United States of America.
[15] R. Vonderheide. The Immune Revolution: A Case for Priming, Not Checkpoint. , 2018, Cancer cell.
[16] M. Cragg,et al. Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies , 2018, Cancer cell.
[17] D. Sansom,et al. CTLA-4: a moving target in immunotherapy. , 2018, Blood.
[18] D. Faustman,et al. Structural principles of tumor necrosis factor superfamily signaling , 2018, Science Signaling.
[19] J. Ravetch,et al. The role of Fc–FcγR interactions in IgG-mediated microbial neutralization , 2015, The Journal of experimental medicine.
[20] U. Klein,et al. Dynamics of B cells in germinal centres , 2015, Nature Reviews Immunology.
[21] Y. Richard,et al. The Signaling Role of CD40 Ligand in Platelet Biology and in Platelet Component Transfusion , 2014, International journal of molecular sciences.
[22] R. Vonderheide,et al. Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer , 2013, Cancer Immunology Research.
[23] R. Kelley,et al. Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys , 2013, mAbs.
[24] Hongmin Li,et al. Functional Interaction of CD154 Protein with α5β1 Integrin Is Totally Independent from Its Binding to αIIbβ3 Integrin and CD40 Molecules* , 2012, The Journal of Biological Chemistry.
[25] B. Meibohm,et al. Characterizing the Impact of Renal Impairment on the Clinical Pharmacology of Biologics , 2012, Journal of clinical pharmacology.
[26] J. Ravetch,et al. Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies , 2011, Science.
[27] S. Paik,et al. Crystallographic and Mutational Analysis of the CD40-CD154 Complex and Its Implications for Receptor Activation* , 2011, The Journal of Biological Chemistry.
[28] R. Mick,et al. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation , 2009, Journal of Translational Medicine.
[29] R. Noelle,et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system , 2009, Immunological reviews.
[30] K. Flaherty,et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] R. Callard,et al. CD40 Is Constitutively Expressed on Platelets and Provides a Novel Mechanism for Platelet Activation , 2003, Circulation research.
[32] A. Tong,et al. Prospects for CD40-directed experimental therapy of human cancer , 2003, Cancer Gene Therapy.
[33] J. Banchereau,et al. CD40‐CD40 ligand , 2000, Journal of leukocyte biology.
[34] P. Parren,et al. The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A. , 2000, Journal of immunology.
[35] T. Schumacher,et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy , 1999, Nature Medicine.
[36] M. Glennie,et al. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help , 1999, Nature Medicine.
[37] Richard A. Flavell,et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling , 1998, Nature.
[38] R. Schmidt,et al. IgG binding sites on human Fc gamma receptors. , 1997, International reviews of immunology.
[39] S R Sprang,et al. Crystallographic Evidence for Dimerization of Unliganded Tumor Necrosis Factor Receptor (*) , 1995, The Journal of Biological Chemistry.
[40] T. Bentley,et al. Multiple binding sites on the CH2 domain of IgG for mouse Fc gamma R11. , 1992, Molecular immunology.